Effects of fibrinogen concentrate administration during severe hemorrhage
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsThorarinsdottir, H R
Sigurbjornsson, F T
Onundarson, P T
Sigurdsson, G H
MetadataShow full item record
CitationActa Anaesthesiol Scand. 2010, 54(9):1077-82
ÚtdrátturBACKGROUND: Fibrinogen concentrate has been shown to improve coagulation in dilutional coagulopathy in experimental studies, but clinical experience is still scarce. The aim of this study was to evaluate laboratory data and the clinical outcome of fibrinogen administration in patients suffering from severe hemorrhage. MATERIALS AND METHODS: A retrospective study over a 3-year observation period of consecutive patients who received a single dose of fibrinogen concentrate but not recombinant factor VIIa as part of their treatment of severe hemorrhage, defined as >6 U of packed red blood cells (PRBCs). RESULTS: Thirty-seven patients were included, most of them suffering from severe hemorrhage following open heart surgery (68%). After a median fibrinogen dose of 2 g (range 1-6 g), an absolute increase in the plasma fibrinogen concentration of 0.6 g/l was observed (P<0.001). The activated partial thromboplastin time (APTT) decreased significantly (P<0.001), from 52 to 43 s and the prothrombin time (PT) decreased from 20 to 17 s, respectively. The transfusion requirement for PRBCs decreased from 6 to 3 U (P<0.01) in the 24 h after fibrinogen administration, but fresh-frozen plasma and platelet concentrate transfusions did not change significantly. Eight patients (22%) died in intensive care unit and the pre-operative fibrinogen concentration was not significantly different in these patients. CONCLUSION: Administration of fibrinogen for severe hemorrhage was associated with an increased fibrinogen concentration and a significant decrease in APTT, PT and the requirement for PRBCs.
Lu00FDsingTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Fibrinogen concentrate substitution therapy for obstetric hemorrhage complicated by coagulopathy.
- Authors: Kikuchi M, Itakura A, Miki A, Nishibayashi M, Ikebuchi K, Ishihara O
- Issue date: 2013 Apr
- Observational study of fibrinogen concentrate in massive hemorrhage: evaluation of a multicenter register.
- Authors: Weiss G, Lison S, Glaser M, Herberger S, Johanning K, Strasser T, Huber T, Spannagl M, Heindl B
- Issue date: 2011 Dec
- Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding.
- Authors: Danés AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB
- Issue date: 2008 Apr
- Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.
- Authors: Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B
- Issue date: 2008 Dec
- Increased thrombin generation and fibrinogen level after therapeutic plasma transfusion: relation to bleeding.
- Authors: Schols SE, van der Meijden PE, van Oerle R, Curvers J, Heemskerk JW, van Pampus EC
- Issue date: 2008 Jan